2014 TAG Update
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
2014 Symposium: Zero Accountability: When Action Doesn’t Match the Numbers
On October 30, 2014, in conjunction with the Union World Conference in Barcelona, Spain, Treatment Action Group (TAG), the Stop TB Partnership, Médecins Sans Frontières (MSF), Partners In Health (PIH), and the Harvard Medical School Department of Global Health and…
Activists Urge Otsuka to Provide Access to TB Drug
Tuberculosis (TB) activists interrupted Otsuka’s symposium at the 45th Conference on World Lung Health, calling for widespread registration of and immediate broad compassionate use access to delamanid, Otsuka’s new drug to treat multidrug-resistant TB (MDR-TB).
Tuberculosis Research at Risk as Big Pharma Shutters Programs
Worldwide governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group.
2014 Report on TB Research Funding Trends
2014 Report on Tuberculosis Research Funding Trends, 2005–2013. 2nd Edition May 18, 2015 By Mike Frick Edited by Mark Harrington and Andrea Benzacar From the Executive Summary Reader beware: funding data presented in this report may be less encouraging than…
Generics vs. the Giant
For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable Erica Lessem As new drugs bedaquiline and delamanid offer renewed hope of treating DR-TB, doctors and programs are faced…
Safeguarding against Stock-Outs
The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets Kenyon Farrow Generic drugs can be credited with saving millions of lives by allowing for…
TAGline Fall 2014
Hello Generics: A Drug by Any Other Name; The Road to Treatment Access; Safeguarding Against Stockouts; Generics vs. the Giant
An Activist’s Guide to Linezolid (Zyvox)
By Erica Lessem and Lauren Volpert September 2014 I. Introduction Increasingly drug-resistant forms of tuberculosis (TB) are becoming more common worldwide, and few medicines are available to treat them.1 Newly developed TB drugs, such as bedaquiline and delamanid, offer some…
An Activist’s Guide to Delamanid (Deltyba)
Tuberculosis (TB) continues to kill over a million people each year, and multidrug-resistant (MDR) TB is a growing problem with few treatment options. In April 2014, delamanid was approved by the European Medicines Agency (EMA) for the treatment of TB, becoming only the second new drug from a new drug class (after bedaquiline) to receive such approval in over forty years.